Revenue Update on Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC)

Cyclacel Pharmaceuticals Inc(NASDAQ:CYCC) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 28, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.69.

Cyclacel Pharmaceuticals Inc (CYCC) made into the market gainers list on Fridays trading session with the shares advancing 7.55% or 0.24 points. Due to strong positive momentum, the stock ended at $3.42, which is also near the day’s high of $3.562. The stock began the session at $3.2361 and the volume stood at 1,29,663 shares. The 52-week high of the shares is $9.72 and the 52 week low is $3.05. The company has a current market capitalization of $15 M and it has 42,51,229 shares in outstanding.

Cyclacel Pharmaceuticals Inc. develops therapies that harness the power of the immune system to treat cancer and other serious illnesses. The Company develops proprietary techniques of antibody engineering to develop antibody-based products for the applications in immunology oncology and infectious diseases. Xcyte Therapies is currently conducting Phase I/II clinical trials in hormone-refractory prostate cancer multiple myeloma and chronic lymphocytic leukemia.

Add Comment